Active substance
Results for the substance tucatinib
2 results
About this active substance
Tucatinib is a medication used in the treatment of advanced or metastatic HER2-positive breast cancer. It is a selective HER2 kinase inhibitor, a protein involved in the growth and proliferation of tumor cells. By blocking HER2 activity, tucatinib helps slow disease progression and reduce tumor size.
Tucatinib is administered orally, usually in combination with other medications such as trastuzumab and capecitabine, to enhance treatment efficacy. The dosage and duration of treatment are determined by the physician based on the stage of the disease and the patient's response.
Common side effects include diarrhea, nausea, fatigue, vomiting, and elevated liver enzyme levels. In rare cases, severe adverse reactions such as liver damage or serious skin reactions may occur. Regular monitoring is essential to assess the safety and effectiveness of the treatment.
Tucatinib is a promising therapeutic option for patients with HER2-positive breast cancer, offering a chance to control the disease and improve their quality of life.
Tucatinib is administered orally, usually in combination with other medications such as trastuzumab and capecitabine, to enhance treatment efficacy. The dosage and duration of treatment are determined by the physician based on the stage of the disease and the patient's response.
Common side effects include diarrhea, nausea, fatigue, vomiting, and elevated liver enzyme levels. In rare cases, severe adverse reactions such as liver damage or serious skin reactions may occur. Regular monitoring is essential to assess the safety and effectiveness of the treatment.
Tucatinib is a promising therapeutic option for patients with HER2-positive breast cancer, offering a chance to control the disease and improve their quality of life.